Development of an artificial α-helical polypeptide adjuvant for dendritic cell activation through cGAS-STING pathway.
발표자
()
초록
내용
The purpose of the development of the artificial alpha-helical polypeptide adjuvant (PA) is to deliver antigen to dendritic cells (DCs). Immature DCs have high antigen uptake capacity and mature at the time of antigen uptake. When we deliver antigen-PA nanoparticles, DCs represent higher expression levels of CD40 and CD86. CD40 and CD86 are DCs cell markers that increase the stimulation of T cells. The cationic alpha-helical polypeptide PA1 (Poly((1-(2-(2-hydroxyethoxy)ethyl)piperazinyl)pentyloxy benzyl-L-lysine) and PA2 (Poly(1-aza-18-crown-6)pentyloxy benzyl-L-lysine) with model antigen ovalbumin (OVA) nanoparticles show higher DC activation capacity than chitosan (CS)-OVA nanoparticle, which is known to have an adjuvant effect.